Genetically determined platelet traits impact stroke risk through multiple mechanisms and cell types

Stroke remains a leading cause of death and disability worldwide. Current antiplatelet and anticoagulant treatments are prone to failure. Heritable blood and platelet traits contribute to stroke risk, but related mechanisms are not fully understood. Platelets bind to damaged endothelial walls to initiate thrombosis, but erythrocyte and leukocyte recruitment are involved in stroke pathogenesis. We aimed to identify causal blood-related cells and mechanisms that modulate stroke risk. By two sample Mendelian Randomization (MR), increased platelet count heightened stroke risk (Odds ratio [OR] 1.03 per 1 SD unit increase in platelet count, P=1×10 -2 ). However, these effects were relatively weak and complicated by similar effects from erythrocyte and leukocyte traits. To ascertain key blood traits that influence stroke, we applied Bayesian Model Averaging (MR-BMA) and identified platelet count and mean platelet volume as key positive regulators for stroke risk. We validated an epidemiologic association between increased platelet count and higher stroke risk among a large patient cohort. Taken together, these findings indicate that platelet traits are the most critical risk factors for stroke, among analyzed blood cell traits. To deconvolute multiple underlying genetic mechanisms by which platelet traits impact stroke risk, we clustered platelet count variants using noise-augmented directional clustering (NAvMix). We identified 13 clusters, two of which were highly predictive for increased stroke risk (OR 1.31 per SD unit increase in platelet count, P<1×10 -6 ). Pathway analyses on eQTLs linked to variants in these subclusters indicated enrichment for endothelial cell adhesion or platelet reactivity. Colocalization analysis of stroke and platelet count loci identified genes implicated in platelet reactivity ( RIN3 ) and peroxisome biogenesis ( PEX6/PEX29 ). These findings reflect complex mechanisms underlying platelet trait variation and reveal key pathways that influence stroke risk through multiple cell types and biological mechanisms, including platelet biology and endothelial cell adhesion. An approach combining novel MR methods with subclustering may be a viable method to ascertain causal mechanisms related to other closely related exposure traits.

Related Concept Videos

Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.5K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
7.1K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
903
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
645